Evidence from human and animal testing suggests the brain-altering effects of psychedelics could be repurposed for treating addiction. Now, researchers at University of California, Davis, and the University of Colorado Anschutz Medical Campus plan to screen hundreds of compounds to discover new, non-hallucinogenic treatments for substance use disorders.
Assistant Professor David Olson has received the American Society for Neurochemistry’s Jordi Folch-Pi Memorial Award. The award is given to an outstanding young investigator who has demonstrated a high level of research competence and originality, has significantly advanced our knowledge of neurochemistry, and shows a high degree of potential for future accomplishments.
The growing popularity of microdosing — taking tiny amounts of psychedelic drugs to boost mood and mental acuity — is based on anecdotal reports of its benefits. Now, a study in rats by researchers at the University of California, Davis, suggests microdosing can provide relief for symptoms of depression and anxiety, but also found potential negative effects.
A team of scientists at the University of California, Davis, is exploring how hallucinogenic drugs impact the structure and function of neurons — research that could lead to new treatments for depression, anxiety and related disorders.
Alexandra Greb, a UC Davis senior in pharmaceutical chemistry from Danville, California, is a co-author on a new study exploring how hallucinogenic drugs affect the structure and function of neurons. The research could lead to new treatments for depression, anxiety and related disorders.
